-
The New England Journal of Medicine Mar 1970
Topics: Arrhythmias, Cardiac; Costs and Cost Analysis; Humans; Myocardial Infarction; Procainamide
PubMed: 5413110
DOI: No ID Found -
Clinical Pharmacokinetics 1977
Topics: Arrhythmias, Cardiac; Biological Availability; Biotransformation; Humans; Procainamide
PubMed: 589880
DOI: 10.2165/00003088-197702060-00001 -
Therapeutic Drug Monitoring Jul 1990We describe a case of procainamide-induced respiratory failure in a myasthenic patient with no prior history of respiratory weakness. Respiratory failure was induced...
We describe a case of procainamide-induced respiratory failure in a myasthenic patient with no prior history of respiratory weakness. Respiratory failure was induced secondary to procainamide alone since no N-acetyl-procainamide level was detectable. The patient's strength rapidly improved and he was successfully extubated 12 h after the offending dose.
Topics: Aged; Humans; Injections, Intravenous; Male; Myasthenia Gravis; Procainamide; Respiratory Insufficiency
PubMed: 2396315
DOI: 10.1097/00007691-199007000-00019 -
Clinical Pharmacology and Therapeutics Nov 1982Procainamide kinetics were studied in six children after a single intravenous dose. Two-compartment kinetic analysis of serum concentration-time curves of five children,...
Procainamide kinetics were studied in six children after a single intravenous dose. Two-compartment kinetic analysis of serum concentration-time curves of five children, who received a dose of 5.5 +/- 0.9 mg/kg (mean +/- SD), revealed the following values for kinetic parameters: distribution half-life, 10.3 +/- 3.4 min; elimination half-life, 1.7 +/- 0.1 hr; elimination constant, 1.2 +/- 0.3 hr-1; plasma clearance 19.4 +/- 2.0 ml/min/kg, and steady-state volume of distribution, 2.2 +/- 0.3 l/kg. A sixth patient, who received an accidental overdose of 28 mg/kg, had altered elimination kinetics due to drug-induced hypotension. N-acetylprocainamide (NAPA) was detected in serum samples obtained soon after procainamide dosing and peak concentrations were attained at 1 to 2 hr. NAPA levels were lower than corresponding procainamide concentrations at most sampling periods. The findings of short elimination half-life and rapid plasma clearance of procainamide in children suggest that continuous intravenous infusion may be necessary to maintain therapeutically effective plasma concentrations in these patients.
Topics: Arrhythmias, Cardiac; Child; Half-Life; Humans; Kinetics; Male; Procainamide; Prospective Studies
PubMed: 7128001
DOI: 10.1038/clpt.1982.210 -
Nursing 2006Learn how to safely give this treatment for ventricular arrhythmias.
Learn how to safely give this treatment for ventricular arrhythmias.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Interactions; Drug Monitoring; Humans; Nurse's Role; Patient Education as Topic; Patient Selection; Procainamide; Tachycardia, Supraventricular; Tachycardia, Ventricular; Ventricular Fibrillation
PubMed: 16641699
DOI: No ID Found -
Archives of Surgery (Chicago, Ill. :... Mar 1961
Topics: Electric Countershock; Heart Ventricles; Humans; Procainamide; Ventricular Fibrillation
PubMed: 13769993
DOI: 10.1001/archsurg.1961.01300090158031 -
JAMA Jun 1975
Topics: Aged; Antibodies, Antinuclear; Atrial Fibrillation; Bundle-Branch Block; Female; Humans; Lupus Erythematosus, Systemic; Male; Neutrophils; Procainamide; Syndrome; Time Factors
PubMed: 48561
DOI: No ID Found -
Anaesthesia and Intensive Care May 1984We report the use of intravenous procainamide infusion in the treatment of fifteen patients with acute atrial fibrillation. Procainamide was infused at 50 mg/min to a...
We report the use of intravenous procainamide infusion in the treatment of fifteen patients with acute atrial fibrillation. Procainamide was infused at 50 mg/min to a maximum of 20 mg/kg, with blood pressure and electrocardiographic monitoring. Ten patients responded, with a mean dose of 8.7 (standard deviation 4.3) mg/kg, four of these reverting to sinus rhythm after a low dose of less than 5.0 mg/kg. Hypotension was a common concomitant and was seen in four cases, but required termination of the infusion only in a patient with cardiomyopathy. An increase in ventricular rate or conversion to atrial flutter was not seen. Intravenous infusion of procainamide is a safe and moderately effective method of cardioversion in acute atrial fibrillation.
Topics: Acute Disease; Adult; Aged; Atrial Fibrillation; Blood Pressure; Electrocardiography; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Procainamide
PubMed: 6476345
DOI: 10.1177/0310057X8401200206 -
Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans.Journal of Cardiovascular Pharmacology Sep 1989Procainamide is a sodium channel blocker which prolongs QRS and QTc intervals, yet its major active metabolite, N-acetylprocainamide (NAPA), generally prolongs only QTc...
Procainamide is a sodium channel blocker which prolongs QRS and QTc intervals, yet its major active metabolite, N-acetylprocainamide (NAPA), generally prolongs only QTc and has very different electrophysiologic and antiarrhythmic actions. In greater than 50% of patients receiving chronic treatment with procainamide, plasma concentrations of NAPA exceed those of procainamide. In this study, we examined the hypothesis that NAPA might alter the disposition kinetics or pharmacologic actions of procainamide. Ten patients with frequent ventricular extrasystoles received intravenous (i.v.) infusions of procainamide alone (study day 1), procainamide and NAPA (study day 2), and NAPA alone (study day 3) at least 48 h apart. On study days 1 and 2, procainamide was administered at a constant rate for 4 h. On study days 2 and 3, NAPA was administered as a loading and maintenance infusion designed to reach a target pseudo-equilibrium plasma concentration of 8 micrograms/ml. NAPA increased procainamide elimination half-life (t1/2) from 275 +/- 42 min (mean +/- SD) on day 1 to 340 +/- 74 min on day 2 (p less than 0.01). A significant correlations was noted between the change in procainamide total clearance on day 2 relative to day 1 and the initial procainamide total clearance on day 1 (r = -0.77, p = 0.009). Findings were similar when procainamide fractional urinary excretion was considered (r = -0.89, p = 0.007). NAPA did not alter procainamide-induced QRS prolongation, but potentiated procainamide-induced QTc prolongation. The antiarrhythmic response to procainamide was not significantly altered by NAPA in seven of nine patients. One patient had greater arrhythmia suppression when NAPA and procainamide were combined than when either was administered alone. In one patient, NAPA apparently antagonized procainamide-induced arrhythmia suppression, but this effect was not reproducible. We conclude that accumulation of NAPA during procainamide therapy can alter both procainamide elimination as well as its electrophysiologic actions.
Topics: Acecainide; Acetylation; Adult; Aged; Arrhythmias, Cardiac; Drug Interactions; Electrocardiography; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Phenotype; Procainamide
PubMed: 2476614
DOI: 10.1097/00005344-198909000-00003 -
Lancet (London, England) Nov 1979
Comparative Study
Topics: Acecainide; Humans; Immune Complex Diseases; Lupus Erythematosus, Systemic; Procainamide
PubMed: 91813
DOI: 10.1016/s0140-6736(79)92473-5